|
WO2021070203A1
|
|
Stable formulation of integrin antibody
|
|
WO2021044327A1
|
|
Solid forms of filgotinib maleate and processes thereof
|
|
WO2020261293A1
|
|
Process for preparation of midostaurin
|
|
WO2020245839A1
|
|
Method for identification and absolute quantification of product-related impurities in a protein using high-resolution mass spectrometry
|
|
WO2020230037A1
|
|
Alternate process for the preparation of encequidar
|
|
WO2020208594A1
|
|
Solid state forms of elafibranor
|
|
WO2020194175A1
|
|
Solid forms of encequidar mesylate and processes thereof
|
|
WO2020174408A1
|
|
Solid state forms of siponimod
|
|
WO2020109938A1
|
|
Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof
|
|
WO2020075027A1
|
|
Process for preparation of eribulin and intermediates thereof
|
|
AU2019322315A1
|
|
Topical oleaginous compositions
|
|
AU2019274827A1
|
|
CTLA4-Ig fusion protein formulation
|
|
AU2019274826A1
|
|
Stable fusion protein formulation
|
|
US2019350948A1
|
|
Stable liquid formulations of cyclophosphamide and its impurities
|
|
AU2019253070A1
|
|
Antibody formulation
|
|
CN112292146A
|
|
Stable formulations of therapeutic antibodies
|
|
CN112243379A
|
|
Stable antibody formulations
|
|
WO2019186440A1
|
|
Topical pharmaceutical compositions of nimesulide
|
|
WO2020128646A1
|
|
Process for the preparation of sartans or salts thereof
|
|
WO2019155396A1
|
|
Sustained release microspheres with low initial burst and methods of preparation thereof
|
